Abstract
Autism spectrum disorder (ASD) is a complex, life-long neurodevelopmental disorder currently affecting an estimated 1 out of 68 among children aged 8 y in the United States. ASD has complex genetic and epigenetic features that lead to the phenotype and there is no single genetic marker for the diagnosis. Therefore, the diagnosis for ASD is phenotype- based with no validated or credible laboratory tests available. Evidence-based treatments for ASD are limited. There is no FDA approved medical therapy that addresses either core ASD symptoms or pathophysiological processes associated with ASD. We outline herein, several ASD-associated basic physiological pathways that can be regulated by the small molecule phytochemical sulforaphane, as an example of a druggable small molecule target for which much in vitro, pre-clinical, and clinical evidence already exists: (1) redox metabolism/oxidative stress, (2) mitochondrial dysfunction, (3) immune dysregulation/neuroinflammation, (4) febrile illness and the heat shock response, and (5) synaptic dysfunction. Furthermore, we identify the biomarkers that can be used to assess the functioning of these pathways as well as suggesting how these biomarkers could guide novel treatment strategies to correct these biochemical abnormalities in order to improve core and associated symptoms of ASD.
Keywords: Heat shock response, mitochondrial dysfunction, neuroinflammation, oxidative stress, sulforaphane, synaptic dysfunction.
CNS & Neurological Disorders - Drug Targets
Title:Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
Volume: 15 Issue: 5
Author(s): Hua Liu, Paul Talalay and Jed W. Fahey
Affiliation:
Keywords: Heat shock response, mitochondrial dysfunction, neuroinflammation, oxidative stress, sulforaphane, synaptic dysfunction.
Abstract: Autism spectrum disorder (ASD) is a complex, life-long neurodevelopmental disorder currently affecting an estimated 1 out of 68 among children aged 8 y in the United States. ASD has complex genetic and epigenetic features that lead to the phenotype and there is no single genetic marker for the diagnosis. Therefore, the diagnosis for ASD is phenotype- based with no validated or credible laboratory tests available. Evidence-based treatments for ASD are limited. There is no FDA approved medical therapy that addresses either core ASD symptoms or pathophysiological processes associated with ASD. We outline herein, several ASD-associated basic physiological pathways that can be regulated by the small molecule phytochemical sulforaphane, as an example of a druggable small molecule target for which much in vitro, pre-clinical, and clinical evidence already exists: (1) redox metabolism/oxidative stress, (2) mitochondrial dysfunction, (3) immune dysregulation/neuroinflammation, (4) febrile illness and the heat shock response, and (5) synaptic dysfunction. Furthermore, we identify the biomarkers that can be used to assess the functioning of these pathways as well as suggesting how these biomarkers could guide novel treatment strategies to correct these biochemical abnormalities in order to improve core and associated symptoms of ASD.
Export Options
About this article
Cite this article as:
Liu Hua, Talalay Paul and W. Fahey Jed, Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD), CNS & Neurological Disorders - Drug Targets 2016; 15 (5) . https://dx.doi.org/10.2174/1871527315666160413120414
DOI https://dx.doi.org/10.2174/1871527315666160413120414 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Erythropoietin and Oxidative Stress
Current Neurovascular Research CD36 and Intestinal Fatty Acid Absorption
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Truncated Human Cathepsin L, Encoded by a Novel Splice Variant, Exhibits Altered Subcellular Localization and Cytotoxicity
Protein & Peptide Letters Potentiating the Naturally Occurring Process for Repair of Damaged Heart
Current Pharmaceutical Design Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease
Current Drug Targets Cardioprotective Effects of the I<sub>f</sub> Current Inhibition by Ivabradine During Cardiac Dysfunction
Current Pharmaceutical Biotechnology 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery Patent Selections
Recent Patents on Biomarkers Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets